Vanda Pharmaceuticals | VNDA - Gross Profit On Sales

Stock Price
7.44
Daily Change
0.02 0.27%
Monthly
0.40%
Yearly
56.63%
Q1 Forecast
4.24

Vanda Pharmaceuticals reported $50.6M in Gross Profit on Sales for its fiscal quarter ending in December of 2024.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 256.99M 13.15M Sep/2025
Agios Pharmaceuticals USD 11.2M 448K Sep/2025
Akebia Therapeutics USD 49.21M 13.25M Mar/2025
Alnylam Pharmaceuticals USD 1.05B 418.14M Sep/2025
Anika Therapeutics USD 14.68M 9.46M Mar/2025
Arrowhead Research USD 256.47M 228.7M Sep/2025
AstraZeneca USD 12.39B 5M Dec/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Enanta Pharmaceuticals -22.29M 23.75M Dec/2024
Esperion Therapeutics USD -29.52M 32.4M Sep/2024
Halozyme Therapeutics USD 281.77M 2.41M Sep/2025
Heron Therapeutics USD 23.35M 1.6M Sep/2024
Insmed USD 111.44M 33.36M Sep/2025
J&J USD 16.6B 118M Dec/2025
Lexicon Pharmaceuticals USD -16.16M 2.89M Jun/2024
Ligand Pharmaceuticals USD 155.28M 82.42M Sep/2025
Merck USD 13.42B 431M Sep/2025
Minerva Neurosciences -4.27M 26.79M Dec/2024
Moderna USD 809M 791M Sep/2025
Novartis USD 10.82B 694M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
PTC Therapeutics USD 187.69M 24.3M Sep/2025
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sanofi EUR 8.45B 1.31B Dec/2025
Takeda JPY 790.55B 262.97B Dec/2025
Teva Pharmaceutical Industries USD 2.66B 351M Dec/2025
Ultragenyx Pharmaceutical USD 131.94M 11.55M Sep/2025
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024
Veracyte USD 91.28M 1.51M Sep/2025